The Roberts Glore & Co. Inc. IL Sold shares of CME Group Inc. (CME)

The Roberts Glore & Co. Inc. IL Sold shares of CME Group Inc. (CME)

Roberts Glore & Co. Inc. IL reduced its stake in shares of CME Group Inc. (NASDAQ:CME) by 9.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,584 shares of the company’s stock after selling 921 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in CME Group were worth $836,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of CME. Quantitative Systematic Strategies LLC acquired a new position in shares of CME Group during the second quarter valued at about $1,027,000. ING Groep NV increased its position in shares of CME Group by 185.7% in the second quarter. ING Groep NV now owns 19,716 shares of the company’s stock valued at $1,920,000 after buying an additional 12,814 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in shares of CME Group by 17.2% in the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 27,578 shares of the company’s stock valued at $2,686,000 after buying an additional 4,042 shares during the last quarter. Capital Fund Management S.A. increased its position in shares of CME Group by 3.1% in the second quarter. Capital Fund Management S.A. now owns 64,514 shares of the company’s stock valued at $6,284,000 after buying an additional 1,910 shares during the last quarter. Finally, Intermede Investment Partners Ltd increased its position in shares of CME Group by 2.0% in the second quarter. Intermede Investment Partners Ltd now owns 362,949 shares of the company’s stock valued at $35,351,000 after buying an additional 7,286 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

CME Group Inc. (NASDAQ:CME) traded up 1.46% on Friday, reaching $105.44. The company’s stock had a trading volume of 1,313,836 shares. The firm’s 50-day moving average price is $106.49 and its 200-day moving average price is $99.63. CME Group Inc. has a 52-week low of $81.87 and a 52-week high of $110.35. The stock has a market cap of $35.73 billion, a price-to-earnings ratio of 26.63 and a beta of 0.83.

CME Group (NASDAQ:CME) last issued its earnings results on Thursday, July 28th. The company reported $1.14 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.03. The firm had revenue of $906 million for the quarter, compared to the consensus estimate of $897.84 million. CME Group had a return on equity of 6.83% and a net margin of 38.22%. The company’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.95 EPS. On average, equities analysts expect that CME Group Inc. will post $4.43 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 26th. Investors of record on Friday, September 9th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 2.28%. The ex-dividend date was Wednesday, September 7th. CME Group’s dividend payout ratio (DPR) is 60.61%.

A number of research firms have recently weighed in on CME. Jefferies Group restated a “buy” rating and set a $118.00 target price on shares of CME Group in a research report on Thursday. Deutsche Bank AG boosted their target price on CME Group from $115.00 to $116.00 and gave the stock a “buy” rating in a research report on Wednesday, October 5th. JPMorgan Chase & Co. set a $116.00 target price on CME Group and gave the stock a “buy” rating in a research report on Monday, September 12th. Zacks Investment Research downgraded CME Group from a “buy” rating to a “hold” rating in a research report on Wednesday, September 7th. Finally, Keefe, Bruyette & Woods boosted their target price on CME Group from $99.00 to $103.00 and gave the stock a “market perform” rating in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. CME Group currently has an average rating of “Hold” and a consensus target price of $103.27.

In related news, Director Martin J. Gepsman sold 300 shares of the firm’s stock in a transaction on Friday, September 2nd. The stock was sold at an average price of $109.00, for a total transaction of $32,700.00. Following the completion of the transaction, the director now directly owns 42,802 shares of the company’s stock, valued at approximately $4,665,418. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Phupinder Gill sold 30,002 shares of the firm’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $110.00, for a total value of $3,300,220.00. Following the transaction, the chief executive officer now directly owns 116,222 shares of the company’s stock, valued at $12,784,420. The disclosure for this sale can be found here. Corporate insiders own 0.61% of the company’s stock.

CME Group Company Profile

CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.

Related posts

Leave a Comment